Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 5/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 5/20 | 0.40 |
| ▸ | BTK | Q06187 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306630 | 0.89 | EGFR (0.42) | MAPK3AURKAMAPK1MAP2K1EGFR | |
| SCHEMBL270219 | 0.84 | TP53 (0.43) | MAPK3AURKASYK | |
| SCHEMBL10261580 | 0.84 | EGFR (0.45) | MAPK3AURKAMAPK1MAP2K1EGFR | |
| SCHEMBL270504 | 0.83 | MAPK8 (0.47) | MAPK3AURKAJAK3SYKJAK1 | |
| SCHEMBL12279068 | 0.83 | ALDH1A1 (0.44) | MAPK3AURKAMAPK1MAP2K1BTK | |
| SCHEMBL270239 | 0.81 | EGFR (0.58) | EGFRBTKJAK3ITKSYK | |
| SCHEMBL263570 | 0.81 | ALDH1A1 (0.42) | MAPK3AURKAMAPK1MAP2K1SCN9A | |
| SCHEMBL270260 | 0.79 | AURKA (0.45) | MAPK3AURKAPKMYT1ALDH1A1 | |
| SCHEMBL270785 | 0.79 | MAPK3 (0.52) | MAPK3AURKAJAK3SYK | |
| SCHEMBL270620 | 0.77 | ULK1 (0.54) | MAPK3AURKAEGFRSYKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | MAPK3 152/4885AURKA 745/4885MAPK1 356/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | MAPK3 122/4885AURKA 75/4885MAPK1 298/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | MAPK3 122/4885AURKA 75/4885MAPK1 298/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | MAPK3 122/4885AURKA 75/4885MAPK1 298/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | MAPK3 122/4885AURKA 75/4885MAPK1 298/4885 |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | MAPK3 1819/4885AURKA 3934/4885MAPK1 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.